Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Skye C. Mayo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1631-9855; OpenAlex author ID A5011285023. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper

Papers 10

  1. Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer. Co-author DOI 10.3390/cancers16213650↗
  2. Socioeconomic and Geographic Disparities in the Referral and Treatment of Pancreatic Cancer at High-Volume Centers. Co-author DOI 10.1001/jamasurg.2022.6709↗
  3. Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic… Co-author DOI 10.1002/cam4.5971↗
  4. Neoadjuvant therapy does not impact the biliary microbiome in patients with pancreatic cancer. Co-author DOI 10.1002/jso.27281↗
  5. The patient's perspective: a qualitative study of individual experience with decision-making, treatment, and recovery for resectable pancreatic cancer. Co-author DOI 10.1007/s00520-021-06690-z↗
  6. Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasin… Co-author DOI 10.3390/cancers14030609↗
  7. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Co-author DOI 10.1002/cncr.26553↗
  8. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. Co-author DOI 10.1016/j.jamcollsurg.2011.09.022↗
  9. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Co-author DOI 10.1007/s13193-011-0073-7↗
  10. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Co-author DOI 10.1245/s10434-011-1745-9↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brett C. Sheppard · 6 shared papers, 2022–2024 · strength 0.98
  2. Charles D. Lopez · 5 shared papers, 2022–2024 · strength 0.79
  3. Aaron J. Grossberg · 4 shared papers, 2022–2023 · strength 0.62
  4. Thomas Lee Sutton · 3 shared papers, 2022–2023 · strength 0.47
  5. Adel Kardosh · 3 shared papers, 2022–2024 · strength 0.43
  6. Ranish K. Patel · 2 shared papers, 2023–2024 · strength 0.34
  7. Emerson Yu-sheng Chen · 2 shared papers, 2022–2023 · strength 0.26
  8. Charles R. Thomas · 2 shared papers, 2022–2023 · strength 0.26
  9. Lauren M. Wancata · 1 shared paper, 2022 · strength 0.19
  10. Lissi Hansen · 1 shared paper, 2022 · strength 0.19
  11. Flavio G. Rocha · 1 shared paper, 2023 · strength 0.18
  12. Shay Behrens · 1 shared paper, 2023 · strength 0.17
  13. Gordon Brent Mills · 1 shared paper, 2024 · strength 0.17
  14. Summer L. Gibbs · 1 shared paper, 2024 · strength 0.17
  15. Lei G. Wang · 1 shared paper, 2024 · strength 0.17
  16. Melissa H. Wong · 1 shared paper, 2024 · strength 0.17
  17. Gina M. Vaccaro · 1 shared paper, 2023 · strength 0.15
  18. Ali Noel Gunesch · 1 shared paper, 2022 · strength 0.11
  19. Christopher R. Deig · 1 shared paper, 2022 · strength 0.11
  20. Joseph M. Herman · 4 shared papers, 2011–2012 · strength 0.10
  21. Barish H. Edil · 4 shared papers, 2011–2012 · strength 0.10
  22. Christopher Lee Wolfgang · 4 shared papers, 2011–2012 · strength 0.10
  23. Richard David Schulick · 4 shared papers, 2011–2012 · strength 0.10
  24. Hari Nathan · 2 shared papers, 2012 · strength 0.06
  25. Timothy Michael Pawlik · 2 shared papers, 2012 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.